Utility of a Proteomic Surrogate for Cardiovascular Outcomes to Predict and Monitor COVID-19 Induced Myocarditis

Paterson, C., Hinterberg, M. A., Morrow, A. J. , Sykes, R. , Mangion, K., Welsh, P. , McConnachie, A. , Sattar, N. , Berry, C. and Williams, S. A. (2022) Utility of a Proteomic Surrogate for Cardiovascular Outcomes to Predict and Monitor COVID-19 Induced Myocarditis. American Heart Association's 2022 Scientific Sessions and the American Heart Association's 2022 Resuscitation Science Symposium, Chicago, Illinois, USA, 04-07 Nov 2022. (doi: 10.1161/circ.146.suppl_1.12132)

Abstract

Introduction: Poorer cardiovascular (CV) health is a risk factor for adverse outcomes from COVID-19, and a proportion of COVID-19 survivors exhibit CV dysfunction including myocardial inflammation after initial recovery. However, biomarker-driven predictors of CV outcomes in COVID-19 are lacking. We recently demonstrated that a proteomic surrogate of CV outcomes (MI, stroke, hospitalization for heart failure, or death within 4 years) is highly predictive of acute COVID-19 severity. The current study expands on this to determine if a proteomic CV risk test associates with myocarditis likelihood in COVID-19 survivors. Methods: The SomaScan® platform was used for plasma proteomic phenotyping in CISCO-19 trial participants (n=154, mean age 55y, 43% Female) at hospital discharge following COVID-19, and at follow-up within 6-months later when comprehensive CV assessment including cardiac MRI for myocarditis adjudication was performed. N=20 (13%) were classified as very likely to have myocarditis at follow-up. We used linear mixed models to test proteomic CV scores at both visits against myocarditis likelihood across COVID-19 recovery and compared the predictive performance of the CV risk score to discriminate myocarditis likelihood to performance of Troponin I (TnI) and NT-proBNP. Results: A 36% relative CV risk reduction was observed during COVID-19 recovery. CV risk scores were significantly higher among those very likely myocarditis positive at follow up (p < 0.05 for effects) (Figure 1). Additionally, the performance of the CV risk test in classifying myocarditis likelihood at follow-up was superior to that of TnI or NT-proBNP (AUC=0.64 vs 0.52 and 0.51, respectively). Conclusions: A proteomic predictor of CV risk has potential to support cardiac screening and monitoring CV health across the course of COVID-19 recovery, with diagnostic specificity superior to that of specific single cardiac biomarkers. Future studies with this approach seem warranted.

• Item Type: Conference or Workshop Item
• Additional Information: Abstract published in Circulation146(Suppl_1): A12132
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Berry, Professor Colin and McConnachie, Professor Alex and Welsh, Professor Paul and Mangion, Dr Kenneth and Sattar, Professor Naveed and Sykes, Dr Robert and Morrow, Dr Andrew
• Authors: Paterson, C., Hinterberg, M. A., Morrow, A. J., Sykes, R., Mangion, K., Welsh, P., McConnachie, A., Sattar, N., Berry, C., and Williams, S. A.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Circulation
• ISSN: 0009-7322
• Published Online: 30 October 2022

Related URLs

• Other
• Other